Abstract
Hexamethonium is a potent anti-hypertensive agent. Its use is associated with prominent and unpleasant side effects, and sometimes with circulatory complications from excessive depressor action. It is suitable for relatively few hypertensive patients, and often fails when renal insufficiency is present. The degree of care required to obtain satisfactory effectiveness is such that the program of treatment becomes too unwieldy for general use.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- MOYER J. H. Hydrallazine (apresoline) hydrochloride; pharmacological observations and clinical results in the therapy of hypertension. AMA Arch Intern Med. 1953 Apr;91(4):419–439. doi: 10.1001/archinte.1953.00240160005002. [DOI] [PubMed] [Google Scholar]
- SCHOTTSTAEDT M. F., SOKOLOW M. The natural history and course of hypertension with papilledema (malignant hypertension). Am Heart J. 1953 Mar;45(3):331–362. doi: 10.1016/0002-8703(53)90147-1. [DOI] [PubMed] [Google Scholar]
- SCHROEDER H. A. Control of hypertension by hexamethonium and 1-hydrazinophthalazine; preliminary observations. AMA Arch Intern Med. 1952 Apr;89(4):523–540. doi: 10.1001/archinte.1952.00240040002001. [DOI] [PubMed] [Google Scholar]
- SMIRK F. H., ALSTAD K. S. Treatment of arterial hypertension by penta- and hexamethonium salts; based on 150 tests on hypertensives of varied aetiology and 53 patients treated for periods of two to fourteen months. Br Med J. 1951 Jun 2;1(4717):1217–1228. doi: 10.1136/bmj.1.4717.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SOKOLOW M., SCHOTTSTAEDT M. F. The management of malignant hypertension. Ann Intern Med. 1953 Apr;38(4):647–666. doi: 10.7326/0003-4819-38-4-647. [DOI] [PubMed] [Google Scholar]